Cataract, Diabetic Retinopathy, Eye Diseases, Glaucoma, Vision Impairment and Blindness
Conditions
Keywords
Vision Screening, Follow-up Eye Care, Vulnerable Populations, New York City
Brief summary
The investigators are conducting a 5-year prospective, 2:1 cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved New York City residents living in affordable housing buildings in Harlem and Washington Heights.
Detailed description
This study aims to increase engagement, detection and management of glaucoma, vision impairment, cataracts, and other eye diseases in vulnerable populations living in New York City. This study considers disparities by race, ethnicity, gender, geography, and socioeconomic status using innovative approaches such as patient navigators. Individuals over the age of 40 living in New York City Housing Authority (NYCHA) Housing buildings are eligible.
Interventions
BEHAVIORALEnhanced Intervention Using Patient Navigators
Enhanced support by patient navigators assisted with follow-up eye exam appointment scheduling and arranging transportation over a 1-year period.
OTHERUsual Care
Usual Care subjects who failed the screening and needed vision correction were given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects did not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
Sponsors
Centers for Disease Control and Prevention
Columbia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Intervention model description
2:1 randomization by housing development
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Individuals over age 40 * Living independently in NYCHA housing building or attending DFTA Senior Center * Willing to answer COVID-19 symptom questions * Willing to consent for 2 vision screening visits at baseline and 12-month follow-up
Exclusion criteria
* Self-reported terminal illness with life expectancy less than 1 year * Inability to provide informed consent due to dementia or other reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects with Visual Acuity Worse than 20/40 | 2 years | Visual acuity (VA) is a measure of the spatial resolution of the visual processing system. Visual acuity will be measured in each eye and measured as ≤20/40 or \>20/40. Since there are two best corrected distance visual acuity measurements per person (right eye and left eye), the visual acuity in the worse eye will be used in the analysis and reported at the patient level, rather than the eye level. Visual acuity analysis will be handled as a dichotomous variable and the proportion of subjects with visual acuity 20/40 or worse will be considered abnormal. |
Countries
United States
Outcome results
None listed